Plasma cell neoplasms Cancer
Conditions
Interventions
Patients are randomised to one of two treatment regimens:
1. Regimen A: Induction chemotherapy with adriamycin, carmustine, melphan and cyclophosphamide (ABCM) repeated every 6 weeks plus daily oral
Sponsors
Medical Research Council (MRC) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged <75 years 2. Myelomatosis defined as having at least two of the following: a. Bone marrow smears or sections showing the presence of a neoplastic plasma cell infiltrate and/or microplasmacytomas b. A paraprotein present in the blood or urine c. Definite lytic bone lesions 2. Patients with equivocal myelomatosis are not eligible 3. No previous cytotoxic chemotherapy, except in the circumstances defined in the protocol 4. Able to tolerate a daily fluid intake of not less than 3 L 5. No contraindications to any of the treatment protocols
Exclusion criteria
Exclusion criteria: Not provided at time of registration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration. | — |
Countries
United Kingdom
Outcome results
None listed